Brian Seal
Biographic Data
| ID | 5540574 |
|---|---|
| NAME | Brian Seal |
| GIVEN NAMES | Brian |
| FAMILY NAME | Seal |
| SIGNATURE | SEAL B |
| AFFILIATIONS | Bayer (United States) |
| ORCID | 0000-0002-4914-6161 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2013 |
| LATEST PUBLICATION YEAR | 2015 |
| H-INDEX | 0 |
Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in Seer-Medicare
BACKGROUND: Metastatic colon cancer (mCC) patients often receive multiple lines of chemotherapy/biological treatment (TX), yet subsequent TX lines have not been sufficiently examined using SEER-Medicare data. We developed an algorithm that identifies the number and type of TX lines received by mCC patients. METHODS: The algorithm rules for detecting TX lines were developed a priori and applied to SEER-Medicare data for 7951 elderly mCC patients, …
Medical Costs Associated with Use of Systemic Therapy in Adults with Colorectal Cancer
BACKGROUND: New cytotoxic agents and regimens, as well as immunotherapeutics, have recently been introduced for treatment of colorectal cancer (CRC). OBJECTIVE: To identify the patient-related and clinical and treatment-related factors associated with higher total health care expenditures in newly diagnosed patients with CRC who are receiving systemic therapy (biologic or chemotherapy) from a commercially insured population. METHODS: A longitudin…
No prominent works on this page.
Medical Costs Associated with Use of Systemic Therapy in Adults with Colorectal Cancer
BACKGROUND: New cytotoxic agents and regimens, as well as immunotherapeutics, have recently been introduced for treatment of colorectal cancer (CRC). OBJECTIVE: To identify the patient-related and clinical and treatment-related factors associated with higher total health care expenditures in newly diagnosed patients with CRC who are receiving systemic therapy (biologic or chemotherapy) from a commercially insured population. METHODS: A longitudin…
Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in Seer-Medicare
BACKGROUND: Metastatic colon cancer (mCC) patients often receive multiple lines of chemotherapy/biological treatment (TX), yet subsequent TX lines have not been sufficiently examined using SEER-Medicare data. We developed an algorithm that identifies the number and type of TX lines received by mCC patients. METHODS: The algorithm rules for detecting TX lines were developed a priori and applied to SEER-Medicare data for 7951 elderly mCC patients, …
Cancer (2 works) · Chemotherapy (2 works) · Colorectal cancer (2 works) · Colorectal Cancer Treatments and Studies (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Cancer Cells and Metastasis (1 work) · Cancer, Lipids, and Metabolism (1 work) · Colorectal Cancer Surgical Treatments (1 work) · Economic and Financial Impacts of Cancer (1 work)